Skip to content
DataLookout
Menu

CROWN-MVNCT07798726

TransCatheter Replacement Of the Mitral Valve With the Novel Cephea Mitral Valve System

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Phase changed: Not specified → Not applicable Show 10 more changesShow less
    • Primary endpoint(s) modified
    • Sponsor changed: [Redacted] to Abbott Medical Devices
    • Trial status changed: Withheld → Recruiting
    • Enrollment changed: None → 565
    • Interventions modified
    • Trial arms changed: 0 → 2
    • Primary completion date: Dec 31, 2031
    • Study completion date: Dec 31, 2035
    • Start date: Oct 21, 2026
    • Study title revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Primary Effectiveness Endpoint
Timeframe: 12 months post index procedure.
Primary Safety Endpoint
Timeframe: 30 days post index procedure

Secondary (3)

Change in mitral regurgitation severity from baseline as assessed by the echocardiography core laboratory.
Change in Quality of Life from baseline as measured by the Kansas City Cardiomyopathy Questionnaire Overall Summary Score
Change in the New York Heart Association Functional Classification of at least one grade from baseline.

Arms and interventions

Mitral Regurgitation CohortExperimental

Inclusive of subjects who have moderate-to-severe or severe Mitral Regurgitation

Mitral Annular Calcification (MAC) CohortExperimental

Inclusive of subjects with mitral valve dysfunction associated with MAC

Devices: Cephea Mitral Valve System

Sites

1 site in 1 country

  • Ascension Via Christi Hospitals WichitaWichita, Kansas, United States